Abnormal microbiota contributes to inflammation and CRC development.
Researchers studied how managing inflammation with an anti-inflammatory treatment would affect colon cancer development in mice. Researchers gave mice with colon cancer anti-tumor necrosis factor, a therapy used to treat inflammatory bowel disease. When mice received the anti-TNF therapy, it lessened inflammation and colon cancer development.
Researchers are building on the research to look for microbial genes or pathways that affect cancer development. They said more work is needed to understand the relationship between therapies, microbiota and cancer development.
Read the study here.
More articles on healthcare:
Tennessee ASC introduces 2nd orthopedics robot — 5 details
ASC opens outside Boston with 4 joint owners — 4 things to know
Make your ASC’s anesthesia program more efficient: 5 strategies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
